MEDS
Income statement / Annual
Last year (2023), TRxADE HEALTH, Inc.'s total revenue was $8.27 M,
a decrease of 27.74% from the previous year.
In 2023, TRxADE HEALTH, Inc.'s net income was -$17.84 M.
See TRxADE HEALTH, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$8.27 M
|
$11.45 M
|
$9.89 M
|
$17.12 M
|
$7.44 M
|
$3.83 M
|
$2.93 M
|
$2.48 M
|
$4.99 M
|
$1.50 M
|
| Cost of Revenue |
$5.67 M |
$6.00 M |
$5.14 M |
$11.42 M |
$2.57 M |
$449,049.00 |
$0.00 |
$16,362.00 |
$1.93 M |
$440,047.00 |
| Gross Profit |
$2.60 M |
$5.45 M |
$4.75 M |
$5.71 M |
$4.87 M |
$3.38 M |
$2.93 M |
$2.47 M |
$3.06 M |
$1.06 M |
| Gross Profit Ratio |
0.31 |
0.48 |
0.48 |
0.33 |
0.66 |
0.88 |
1 |
0.99 |
0.61 |
0.71 |
| Research and Development
Expenses |
$1.38 M
|
$1.16 M
|
$1.37 M
|
$662,726.00
|
$647,140.00
|
$949,948.00
|
$375,172.00
|
$286,757.00
|
$319,443.00
|
$319,443.00
|
| General & Administrative
Expenses |
$8.48 M
|
$7.05 M
|
$8.81 M
|
$7.49 M
|
$4.38 M
|
$2.35 M
|
$2.27 M
|
$3.30 M
|
$3.70 M
|
$2.11 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$147,630.00
|
$355,116.00
|
$374,619.00
|
| Selling, General &
Administrative Expenses |
$8.48 M
|
$7.05 M
|
$8.81 M
|
$7.49 M
|
$4.38 M
|
$2.35 M
|
$2.27 M
|
$3.45 M
|
$4.05 M
|
$2.49 M
|
| Other Expenses |
$14,543.00 |
$1.60 M |
-$1.23 M |
$3.25 M |
$72,075.00 |
$161,639.00 |
$67,500.00 |
$131,268.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$9.86 M |
$8.21 M |
$8.81 M |
$7.49 M |
$4.38 M |
$3.30 M |
$2.27 M |
$3.45 M |
$4.05 M |
$2.49 M |
| Cost And Expenses |
$15.54 M |
$14.20 M |
$13.96 M |
$18.90 M |
$6.94 M |
$3.75 M |
$2.27 M |
$3.47 M |
$5.98 M |
$2.93 M |
| Interest Income |
$4,198.00 |
$20,989.00 |
$23,590.00 |
$29,389.00 |
$53,227.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$1.20 M |
$336,206.00 |
$23,590.00 |
$29,389.00 |
$53,227.00 |
$57,541.00 |
$157,056.00 |
$151,500.00 |
$130,136.00 |
$4,154.00 |
| Depreciation &
Amortization |
$1.05 M
|
$194,704.00
|
$138,909.00
|
$102,520.00
|
$94,731.00
|
$87,616.00
|
-$395,095.00
|
$8,667.00
|
$3,802.00
|
$4,800.00
|
| EBITDA |
-$13.72 M
|
-$1.85 M
|
-$5.15 M
|
-$2.51 M
|
$660,550.00
|
$96,654.00
|
$288,983.00
|
-$984,030.00
|
-$133,268.00
|
-$2.00 M
|
| EBITDA Ratio |
-0.75 |
-0.22 |
-0.52 |
-0.1 |
0.09 |
0.06 |
0.25 |
-0.4 |
-0.2 |
-0.95 |
| Operating Income Ratio
|
-0.88
|
-0.24
|
-0.54
|
-0.1
|
0.08
|
-0.02
|
0.13
|
-0.4
|
-0.2
|
-0.96
|
| Total Other
Income/Expenses Net |
-$6.46 M
|
-$362,723.00
|
-$23,590.00
|
-$29,389.00
|
-$778,172.00
|
$96,654.00
|
-$106,112.00
|
-$165,829.00
|
-$119,512.00
|
-$580,571.00
|
| Income Before Tax |
-$13.72 M |
-$3.91 M |
-$5.32 M |
-$2.54 M |
-$284,428.00 |
$9,038.00 |
$288,983.00 |
-$1.17 M |
-$1.12 M |
-$2.01 M |
| Income Before Tax Ratio
|
-1.66
|
-0.34
|
-0.54
|
-0.15
|
-0.04
|
0
|
0.1
|
-0.47
|
-0.22
|
-1.34
|
| Income Tax Expense |
$5.34 M |
$400,337.00 |
-$1.20 M |
$29,389.00 |
$125,302.00 |
-$154,195.00 |
-$50,944.00 |
$1.62 M |
$130,136.00 |
$576,417.00 |
| Net Income |
-$17.84 M |
-$4.31 M |
-$4.11 M |
-$2.57 M |
-$409,730.00 |
$9,038.00 |
$288,983.00 |
-$2.76 M |
-$1.12 M |
-$2.01 M |
| Net Income Ratio |
-2.16 |
-0.38 |
-0.42 |
-0.15 |
-0.06 |
0 |
0.1 |
-1.11 |
-0.22 |
-1.34 |
| EPS |
-23.35 |
-7.63 |
-7.58 |
-4.99 |
-1.04 |
0.0233 |
0.81 |
-7.89 |
-3.2 |
-6.3 |
| EPS Diluted |
-7.49 |
-7.63 |
-7.58 |
-4.99 |
-1.04 |
0.0233 |
0.81 |
-7.87 |
-3.2 |
-6.07 |
| Weighted Average Shares
Out |
$764,058.00
|
$564,863.00
|
$542,450.00
|
$513,708.00
|
$395,273.00
|
$388,430.00
|
$355,060.00
|
$349,641.00
|
$349,641.00
|
$319,371.00
|
| Weighted Average Shares
Out Diluted |
$2.38 M
|
$564,863.00
|
$542,450.00
|
$513,708.00
|
$395,273.00
|
$388,428.00
|
$378,736.00
|
$350,499.00
|
$349,641.00
|
$331,456.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
